A Phase 2b, Multi-Center, Randomized, Placebo-Controlled Double-Blind Study to Investigate the Safety and Efficacy of 16 Weeks of Four Different Regimens of Once-Weekly MET097 in Participants with Obesity and Overweight
Latest Information Update: 10 Dec 2024
Price :
$35 *
At a glance
- Drugs MET 097 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Metsera
- 13 Nov 2024 Status changed from planning to recruiting, according to a Metsera media release.
- 01 Oct 2024 New trial record
- 24 Sep 2024 According to a Metsera media release, the company plans to initiate this Phase 2b trial of MET-097 in Q4 2024, with data anticipated in the first half of 2025.